“The credit outlook for the Indian pharmaceutical industry remains Stable led by healthy accruals, low leverage levels and healthy liquidity profile of the pharmaceutical companies.
ICRA expects the credit metrics of its sample set of Indian pharmaceutical companies to remain comfortable despite higher capital expenditure and R&D expenses.
Furthermore, the liqudiity profile of these companies is also expected to remain comfortable," Jain said.Never miss a story!